Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

53 results
Display

An anesthetic management of head and neck cancer reconstructive surgery in a patient having hemophilia A: a case report

Ryoo SH, Kwon D, Lee JH, Seo KS, Kim HJ, Karm MH

Hemophilia A is a hemorrhagic disease caused by coagulation factor VIII deficiency. In head and neck cancer surgery, especially during a reconstructive one, complications can occur. These include hematomas due...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Acquired Hemophilia A with Gastrointestinal Bleeding

Park N, Jang JS, Cha JH

Peptic ulcer disease is the most common cause of acute gastrointestinal bleeding, followed by variceal bleeding, Mallory–Weiss syndrome, and malignancy. On the contrary, acquired hemophilia A is a very rare...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A

Kim JY, You CW

BACKGROUND: Risk factors for the development of inhibitors in previously untreated patients (PUPs) have been reported; this is not the case in previously treated patients (PTPs) owing to fewer studies....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients

You CW, Baek HJ, Park SK, Park YS, Shin HJ, Engl W, Tangada S

BACKGROUND: The efficacy and safety of extended half-life, full-length, pegylated recombinant factor VIII rurioctocog alfa pegol [BAX 855, ADYNOVATE (USA)/ADYNOVI (Europe); Baxalta US Inc., a Takeda company, Lexington, MA, USA]...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hemophilia A in a Female Patient with Recurrent Vitreous Hemorrhage

Kim HJ, Nam MS, Choo HK, Kim SH

PURPOSE: To report a case of recurrent intraocular hemorrhage due to type A hemophilia in a female patient without any previous medical history. CASE SUMMARY: A 51-year-old female patient without any...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Spontaneous Retroperitoneal Hemorrhage Caused by Idiopathic Acquired Hemophilia A Misdiagnosed as a Delayed Traumatic Hematoma: A Case Report

Kim SH, Park SJ, Park CI, Choi SU, Kim JH

Acquired hemophilia A (AHA) is a rare disease where typically coagulation factor VIII is inhibited by autoantibodies. It occurs in patients with no personal or familial history of bleeding. In...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Perioperative Management of Patients with Hemophilia during Spinal Surgery

Kobayashi , Imagama S, Ando K, Ito K, Tsushima M, Morozumi M, Tanaka S, Machino M, Ota K, Nishida Y, Ishiguro N

STUDY DESIGN: Single-center retrospective study. PURPOSE: To optimize the perioperative management of patients with hemophilia who are undergoing spinal surgery. OVERVIEW OF LITERATURE: Hemophilia is a rare disease in which there is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A case report spontaneous spinal epidural hematoma diagnosed in a hemophilic child with neck pain

Lee HJ

Hemophilia is a disease that causes a hemorrhagic tendency due to a congenital deficiency of blood clotting factors. Hemorrhagic arthritis is the most common complication in hemophilia patients, and hemorrhage...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Progress of Hemophilia A Therapeutics in Korea

Kim DH, Kim SK

Over the past several decades, hemophilia treatment in Korea has progressed dramatically. It has become possible to prevent hemophilia complications by maintenance treatment as well as on-demand treatment with the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX

Yoo KY, Jung SY, Hwang SH, Lee SM, Park JH, Nam HJ

BACKGROUND: Korean National Health Insurance reimburses factor VIII (FVIII) and factor IX (FIX) clotting factor concentrate (CFC) infusions to discrepant activity levels, allowing elevation of FVIII activity to 60 IU/dL...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene Fâ„¢) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study

Kim SK, Yoo KY, Lee KS, Hwang T, Choi YM, Choi EJ, Park SK

BACKGROUND: New B-domain deleted third generation recombinant factor VIII (FVIII; GreenGene Fâ„¢, beroctocog alfa) was launched in 2010. We determined safety and efficacy of GreenGene Fâ„¢ during routine clinical practice...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bone Density Status in Bleeding Disorders: Where Are We and What Needs to Be Done?

Mansouritorghabeh H, Rezaieyazdi Z

Bleeding disorders, including hemophilia, can be seen in every ethnic population in the world. Among various bleeding disorders, reduced bone density has been addressed in hemophilia A. In recent years,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Acquired Hemophilia A Combined with Systemic Lupus Erythematosus: A Case Report and Literature Review

You J, Kim H, Park JS, Chang MH, Lee CH

Acquired hemophilia A (AHA) is a rare hemorrhagic disorder caused by autoantibodies against factor VIII (FVIII). An 80-year-old woman presented multiple bruises on her upper and lower extremities, along with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center

Yoo KY, Joo SC, Choi YM

BACKGROUND: Immune tolerance induction (ITI) can reduce inhibitors against factor VIII concentrates by 70-80%. In this study, we elucidated the characteristics of inhibitors and attempted to determine the proper indications...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A

Hyun SY, Park SY, Lee SY, Kook H, Paik SH, Jang IJ, Lee KS

PURPOSE: Beroctocog alfa is a second generation recombinant factor VIII manufactured by removing the B-domain from factor VIII. This prospective clinical trial was conducted to evaluate the efficacy, safety, and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hemophilia A in a Senior Patient: A Case Report of Spinal Epidural Hematoma as First Presentation

Ahn DK, Jung WS, Lee JI

Hemophilia A is a hereditary coagulation disorder. Most cases are diagnosed at birth or at least during childhood. A spontaneous spinal epidural hematoma was developed in a 74-year-old male patient...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Human coagulation factor VIII domain-specific recombinant polypeptide expression

Choi SJ, Jang KJ, Lim JA, Kim HS

BACKGROUND: Hemophilia A is caused by heterogeneous mutations in F8. Coagulation factor VIII (FVIII), the product of F8, is composed of multiple domains designated A1-A2-B-A3-C1-C2. FVIII is known to interact...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis C virus infection in patients with hemophilia in Korea: Is antiviral therapy effective and safe?

Rou WS, Lee BS

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immune tolerance induction in patients with severe hemophilia A with inhibitors

Ryu JE, Park YS, Yoo KY, Lee KD, Choi YM

BACKGROUND: Inhibitory antibodies to factor VIII (FVIII) are an important complication when managing patients with hemophilia A. Immune tolerance induction (ITI) has been regarded as a useful method for eradicating...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Unexpected Bleeding Following Endoscopic Sinus Surgery Leading to the Rare Diagnosis of Acquired Haemophilia A

Ahn SH, Kim YW, Im DH, Kim JK

We report a case of acquired hemophilia A following endoscopic sinus surgery. The patient was a 64-year-old man whose preoperative activated partial thromboplastin time (aPTT) was slightly prolonged. He underwent...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr